Division of Geriatric Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Department of Physical Therapy, College of Applied Health Sciences, University of Illinois at Chicago, Chicago, Illinois.
Am J Physiol Heart Circ Physiol. 2022 Nov 1;323(5):H975-H982. doi: 10.1152/ajpheart.00435.2022. Epub 2022 Sep 23.
Endothelial function (brachial artery flow-mediated dilation [FMD]) is reduced in estrogen-deficient postmenopausal women, mediated, in part, by reduced nitric oxide (NO) bioavailability, secondary to tetrahydrobiopterin (BH) deficiency and oxidative stress. FMD is increased, but not fully restored, in postmenopausal women after acute intravenous vitamin C (VITC; superoxide scavenger) or oral BH supplementation. In vitro studies demonstrate that coadministration of VITC with BH prevents endothelial nitric oxide synthase (eNOS) uncoupling and reductions in NO by peroxynitrite. To investigate mechanisms of endothelial dysfunction in women, we assessed the separate and combined effects of VITC and BH to determine whether coadministration of VITC + BH improves FMD in healthy postmenopausal women ( = 19, 58 ± 5 yr) to premenopausal ( = 14, 36 ± 9 yr) levels, with exploratory testing in perimenopausal women ( = 8, 51 ± 3 yr). FMD was measured during acute intravenous infusions of saline (control) and VITC (∼2-3 g) ∼3 h after a single dose of oral BH (KUVAN, 10 mg/kg body wt) or placebo (randomized crossover, separated by ∼1 mo). Under the placebo condition, FMD was reduced in postmenopausal compared with premenopausal women during the saline infusion (5.6 ± 0.7 vs. 11.6 ± 0.9%, < 0.001) and increased in postmenopausal women during VITC (+3.5 [1.4, 5.6]%, = 0.001) and acute BH (+1.8 [0.37, 3.2]%, = 0.01) alone. Coadministration of VITC + BH increased FMD in postmenopausal women (+3.0 [1.7, 4.3]%, < 0.001), but FMD remained reduced compared with premenopausal women ( = 0.02). Exploratory analyses revealed that VITC + BH did not restore FMD in perimenopausal women to premenopausal levels ( = 0.045). Coadministration of VITC + BH does not restore FMD in menopausal women, suggesting that additional mechanisms may be involved. Endothelial function is reduced across the menopausal stages related to increased oxidative stress associated with estrogen deficiency. In vitro studies demonstrate that coadministration of VITC with BH prevents endothelial nitric oxide synthase (eNOS) uncoupling and reductions in NO by peroxynitrite; however, this remains untested in humans. We demonstrate that the coadministration of BH + VITC does not restore endothelial function in perimenopausal and postmenopausal women to the level of premenopausal women, suggesting that other mechanisms contribute.
内皮功能(肱动脉血流介导的扩张 [FMD])在雌激素缺乏的绝经后妇女中降低,部分原因是四氢生物蝶呤(BH)缺乏和氧化应激导致一氧化氮(NO)生物利用度降低。在绝经后妇女中,静脉内急性给予维生素 C(VITC;超氧化物清除剂)或口服 BH 补充剂后,FMD 增加,但未完全恢复。体外研究表明,VITC 与 BH 联合给药可防止内皮型一氧化氮合酶(eNOS)解偶联和过氧亚硝酸盐引起的 NO 减少。为了研究女性内皮功能障碍的机制,我们评估了 VITC 和 BH 的单独和联合作用,以确定 VITC+BH 的联合给药是否可以改善健康绝经后妇女(n=19,58±5 岁)的 FMD 至绝经前水平(n=14,36±9 岁),并在围绝经期妇女中进行探索性测试(n=8,51±3 岁)。在单次口服 BH(KUVAN,10mg/kg 体重)或安慰剂(随机交叉,间隔约 1 个月)后 3 小时,通过急性静脉输注盐水(对照)和 VITC(约 2-3g)测量 FMD。在安慰剂条件下,与绝经前妇女相比,绝经后妇女在盐水输注期间 FMD 降低(5.6±0.7%比 11.6±0.9%,<0.001),在 VITC(+3.5[1.4,5.6]%,=0.001)和急性 BH(+1.8[0.37,3.2]%,=0.01)单独给药期间增加。VITC+BH 的联合给药增加了绝经后妇女的 FMD(+3.0[1.7,4.3]%,<0.001),但与绝经前妇女相比,FMD 仍降低(=0.02)。探索性分析显示,VITC+BH 并未将围绝经期妇女的 FMD 恢复到绝经前水平(=0.045)。VITC+BH 的联合给药并未将绝经后妇女的 FMD 恢复到绝经前水平,这表明可能涉及其他机制。与雌激素缺乏相关的氧化应激增加,导致绝经后各阶段的内皮功能降低。体外研究表明,VITC 与 BH 联合给药可防止内皮型一氧化氮合酶(eNOS)解偶联和过氧亚硝酸盐引起的 NO 减少;然而,这在人类中尚未得到验证。我们证明,BH+VITC 的联合给药并不能将围绝经期和绝经后妇女的内皮功能恢复到绝经前妇女的水平,这表明其他机制也起作用。